Hypersensitivity. History of recurrent neutropenia or agranulocytosis. Concomitant use of medicinal products associated w/ neutropenia or those that can cause agranulocytosis. Pregnancy & lactation.
Monitor neutrophil count wkly; interrupt therapy & monitor neutrophil more frequently if patient develops infection. Do not initiate treatment if patient is neutropenic or has a baseline absolute neutrophil count <1.5 x 109/L. Obtain CBC w/ WBC count, corrected for the presence of nucleated RBC, neutrophil & platelet count immediately upon diagnosis of neutropenia & repeat daily; continue for 3 consecutive wk following recovery. Rechallenge is not recommended in the event of neutropenia & contraindicated in agranulocytosis. Monitor serum ferritin conc or other body Fe load indicators every 2-3 mth; plasma Zn conc. Consider treatment interruption if serum ferritin falls <500 mcg/L. HIV +ve or other immunocompromised patients. Consider treatment interruption if there is persistent increase in serum ALT. Carefully monitor liver histology in thalassaemia patients. Urine may show reddish/brown discoloration due to the excretion of Fe-deferiprone complex. Renal or hepatic impairment. Women of childbearing potential must be advised to avoid pregnancy & take contraceptive measures. Lactation. Neurological disorders in childn. Childn <6 yr. Oral soln: Allergic reactions may occur due to sunset yellow (E110) colouring agent.
Potential interactions w/ trivalent cation-dependent medicinal products eg, Al-based antacids. Concurrent use w/ vit C. Do not take medicinal products associated w/ neutropenia or those that can cause agranulocytosis.
Sign Out
